Catalyst Pharmaceuticals 2026 EPS Estimate Jumps to $2.82; Shares Up 22%
Catalyst Pharmaceuticals’ 2026 EPS estimate rose from $2.53 to $2.82 over the last 60 days and shares have climbed 22.4% in the past six months. The company has beaten consensus earnings estimates in each of the trailing four quarters with an average surprise of 35.19%.
1. EPS Estimate Revisions
Over the past 60 days, analysts have revised Catalyst Pharmaceuticals’ 2026 earnings per share forecast upward from $2.53 to $2.82, reflecting heightened confidence in the company’s revenue and margin outlook for its core therapies.
2. Share Performance
Catalyst’s stock has surged 22.4% over the past six months, driven by consistent earnings beats and positive sentiment around its product portfolio for rare neuromuscular and neurological conditions.
3. Earnings Surprises
The company topped consensus earnings estimates in each of the last four quarters, delivering an average surprise of 35.19%, underpinned by stronger-than-expected net product sales and tight expense controls.